A neoplasm is any abnormal mass of tissue that arises when cells multiply faster than they should or fail to die when they normally would. The word literally means “new growth,” and it covers everything from a harmless skin mole to an aggressive lung cancer. What separates a neoplasm that sits quietly in one spot from one that spreads through the body comes down to a handful of biological behaviors, and the causes behind those behaviors range from inherited genetic faults to chemical exposures to chronic infections.
What Makes a Growth a Neoplasm
Normal tissues grow, repair themselves, and then stop. A neoplasm forms when that stop signal breaks down. The cells keep dividing even after the original trigger for growth is gone, producing a mass that the body did not plan for and does not need. Not every neoplasm is a visible lump you can feel. Some grow inside organs, some circulate as abnormal blood cells, and some exist only as microscopic clusters detected under a microscope during a biopsy.
Because the word covers such a wide spectrum, clinicians classify neoplasms by how they behave. The most fundamental split is between benign and malignant growths, but a meaningful gray zone sits between them, which matters both for diagnosis and for treatment decisions.
Benign Versus Malignant Growths
A benign neoplasm grows in a contained, orderly fashion. It typically stays wrapped in a capsule of connective tissue, pushes neighboring structures aside rather than burrowing into them, and does not send cells to distant organs. Common examples include uterine fibroids, lipomas (fatty lumps under the skin), and many thyroid nodules. Benign tumors can still cause problems if they press on nerves, block airways, or produce excess hormones, but they do not invade or metastasize.
A malignant neoplasm, by contrast, invades the tissue around it and can spread to distant sites through the bloodstream or lymphatic system. That capacity for invasion and metastasis is the defining trait of cancer. The cells in a malignant tumor tend to look less organized under a microscope, divide more rapidly, and recruit their own blood supply more aggressively. Research on thymic tumors illustrates the connection between blood vessel growth and invasiveness: noninvasive thymomas averaged roughly five microvessels per unit area, invasive thymomas averaged about twelve, and thymic carcinomas averaged around thirty-four, showing a clear step-up in blood vessel density as tumors become more aggressive.1PubMed. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors
Experimental work has shown that this relationship can run in reverse, too. When tumor cells were engineered to produce a protein called SEMA3F that repels blood vessel growth, the resulting tumors became well-encapsulated, with thick borders of collagen and fibroblasts, and contained roughly half the vessels of control tumors. In effect, cutting off the blood supply pushed the tumor toward a benign-looking, nonmetastatic form.2JCI Insight. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype
How Malignant Cells Invade and Spread
Invasion is the process by which cancer cells break through the normal boundaries of the tissue they started in. Researchers have identified two broad patterns of cancer cell movement: collective migration, where groups of cells move together as a sheet or strand, and individual cell migration, where single cells break away and navigate through surrounding tissue on their own. Individual migrating cells can switch between two styles of movement, one that resembles how fibroblasts crawl and another that resembles the flowing, shape-shifting motion of amoebas.3PubMed Central. Cancer Invasion: Patterns and Mechanisms
For either pattern to succeed, cells need to break down the structural scaffolding between normal tissues. This involves disrupting the adhesion molecules that normally glue cells together and degrading the mesh of proteins outside cells that acts as a physical barrier. As tumors become more aggressive, they increasingly exploit these mechanisms to push through tissue boundaries and establish secondary growths at sites far from where they originated.4Current Molecular Medicine. Molecular Mechanisms of Tumor Invasion and Metastasis: An Integrated View That distant colonization, metastasis, is what makes cancer lethal in most cases. A primary tumor confined to one organ is often surgically removable; metastatic disease scattered across multiple organs is far harder to treat.
The Borderline Category
Not every neoplasm falls neatly into benign or malignant. Borderline tumors sit in an uncomfortable middle ground. They show some features of malignancy under the microscope, like atypical cell architecture, but lack clear-cut invasion into surrounding tissue. Borderline ovarian tumors are a well-known example. They are a diverse group of noninvasive growths with uncertain malignant potential, and while they have a much better outlook than ovarian cancer, a small fraction can recur or behave aggressively.5PubMed Central. Diagnosis, treatment, and follow-up of borderline ovarian tumors
Similar classification challenges exist in the thyroid. In the most recent edition of the WHO classification of thyroid tumors, certain encapsulated follicular-patterned growths were assigned a behavior code of 1, meaning “borderline or uncertain behavior,” rather than being labeled benign (code 0) or malignant (code 3).6PubMed Central. How to handle borderline/precursor thyroid tumors in management of patients with thyroid nodules For patients, this ambiguity can be anxiety-provoking, but it reflects genuine biological reality: some growths genuinely occupy a spectrum between benign and malignant rather than belonging clearly to one camp.
Pathologists face this challenge regularly. Even among experts, agreement on whether a given specimen represents low-grade or high-grade abnormality is imperfect. The Vienna classification for gastrointestinal neoplasms was developed partly to reduce disagreement by grouping lesions into five categories ranging from “negative for neoplasia” through “invasive neoplasia.” When pathologists used this system, agreement improved substantially, reaching about 71% for gastric specimens and about 65% for colorectal ones.7BMJ Journals. The Vienna classification of gastrointestinal epithelial neoplasia
Genetic Causes of Neoplasia
At its core, cancer is a disease of DNA. Every cell carries genes that promote growth and genes that restrain it, and a neoplasm develops when the balance between those two categories tips in favor of unchecked division. Growth-promoting genes, when mutated or overactive, are called oncogenes. Growth-restraining genes, when knocked out or silenced, are called tumor suppressors. Cancer typically involves both: the accelerator stuck down and the brakes cut at the same time.8PubMed Central. Exploring the Genetic Orchestra of Cancer: The Interplay Between Oncogenes and Tumor-Suppressor Genes
These genetic changes do not happen all at once. The transformation from a normal cell to a fully malignant one is stepwise, accumulating mutations over years or decades. A cell might first lose one tumor-suppressor gene, then gain an activating mutation in an oncogene, then lose another checkpoint. Each step gives the cell a slight growth advantage, and natural selection among cells does the rest. This gradual accumulation helps explain why cancer is overwhelmingly a disease of aging: the longer cells divide, the more opportunities mutations have to pile up.
Beyond changes to the DNA sequence itself, chemical modifications on top of DNA play a major role. These epigenetic alterations do not change the letters of the genetic code but change which genes are turned on or off. One of the best-studied epigenetic mechanisms in cancer is DNA methylation. Cancer cells show a characteristic pattern of losing methylation across large stretches of their genome while gaining methylation at specific regulatory sites, which can silence tumor-suppressor genes without mutating them.9Trends in Genetics. DNA Methylation in Cancer This dynamic regulation of methylation is now understood to be a critical mechanism in how cancer starts, persists, and progresses.10PubMed Central. The Role of DNA Methylation in Cancer
When the machinery that maintains and repairs DNA itself is faulty, the result is genomic instability: an elevated rate of new mutations across the genome. Defects in DNA repair pathways predispose cells to accumulating the very mutations that drive malignant transformation, creating a kind of positive feedback loop.11PubMed Central. Genomic Instability and Cancer
Environmental and Chemical Carcinogens
Many cancers trace back to exposures rather than inherited genes. Chemical carcinogens, substances that damage DNA, are among the most studied environmental causes. These chemicals can produce a range of DNA injuries: breaks in one or both strands, bulky chemical groups stuck onto DNA bases (called adducts), and abnormal cross-links between DNA strands or between DNA and nearby proteins.12PubMed Central. Carcinogens and DNA damage
The formation of DNA adducts, where a carcinogen physically bonds to DNA, is considered one of the earliest events in the initiation phase of cancer. The damage is not random: different chemicals tend to hit specific bases and positions within the genetic sequence, and repair efficiency varies depending on where the damage sits.13PubMed. The role of DNA adducts in chemical carcinogenesis A single brief exposure rarely causes cancer on its own. Cancer-inducing exposures tend to be frequent or chronic over years, and the steady accumulation of DNA damage is generally considered necessary for a tumor to develop.14PubMed Central. Chemical-induced DNA damage and human cancer risk
Tobacco smoke is the most familiar example: it contains dozens of carcinogens that form DNA adducts in the lungs, mouth, throat, and bladder over years of use. Ultraviolet radiation from sunlight damages DNA in skin cells. Asbestos fibers cause chronic irritation and DNA damage in lung and pleural tissue. In each case, the pattern is the same: repeated injury, imperfect repair, and gradual accumulation of mutations that eventually tip a cell toward uncontrolled growth.
Chronic Inflammation and Oxidative Stress
You do not always need an external chemical to damage DNA. The body’s own inflammatory response can do it. When tissues are chronically inflamed, immune cells release highly reactive molecules, free radicals and other oxidizing agents, as part of their attack on infection or injury. In small doses and short bursts, this is useful. But when inflammation persists for months or years, those reactive molecules can directly damage DNA in nearby healthy cells, and they can also interfere with the cell’s ability to repair the damage.15PubMed. Chronic inflammation and oxidative stress in human carcinogenesis
This creates a destructive cycle. Damaged cells release signals that attract more inflammatory cells, which produce more free radicals, which cause more DNA damage. Over time, sustained oxidative stress activates pathways that help cells survive when they should die, promotes the growth of new blood vessels to feed expanding tissue, and pushes normal cells toward malignant transformation.16PubMed Central. Oxidative stress, inflammation, and cancer: how are they linked? This is why conditions involving long-standing inflammation, such as ulcerative colitis, chronic hepatitis, and Barrett’s esophagus, carry elevated cancer risk in the affected tissue.
Infections That Drive Neoplasia
A meaningful share of cancers worldwide are triggered by infectious agents, mostly viruses but also some bacteria and parasites. Human papillomavirus (HPV) drives the majority of cervical cancers. Hepatitis B and C viruses cause liver cancer. Helicobacter pylori, a bacterium that colonizes the stomach lining, is a recognized cause of gastric cancer and certain lymphomas. Epstein-Barr virus is linked to several lymphomas and nasopharyngeal carcinoma.
These very different organisms share a common theme: they have evolved ways to interfere with the host cell’s DNA-repair pathways, block programmed cell death, and promote runaway proliferation. By disabling the safety mechanisms that would normally force a damaged cell to either fix itself or self-destruct, these microorganisms create conditions where mutations accumulate and malignant transformation becomes more likely.17PubMed Central. Viruses and Bacteria Associated with Cancer: An Overview The lag between infection and cancer is often decades, which is part of why the connection between infection and cancer was so slow to be recognized historically.
How Tumors Dodge the Immune System
If genetic mutations are the fuel for neoplasia, immune evasion is the permission slip. The immune system routinely destroys cells that look abnormal, and most early neoplastic cells are probably caught and eliminated before they ever become a detectable tumor. Cancer only succeeds when malignant cells find ways to slip past immune surveillance.
A useful framework describes three strategies tumors use. The first is camouflage: cancer cells downregulate or hide the surface markers that immune cells use to recognize threats. The second is coercion: tumors release signals that actively suppress or exhaust nearby immune cells, rendering them ineffective. The third is cytoprotection: malignant cells develop internal defenses that make them resistant to the killing mechanisms immune cells deploy.18Cancer Cell. The “three Cs” of cancer immune evasion In addition, tumors can reshape their local environment by depleting nutrients that immune cells need and flooding the area with metabolites that blunt immune function.19PubMed Central. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
This is why immunotherapy, which aims to remove the brakes tumors place on immune cells, has been one of the most significant advances in cancer treatment in recent years. By blocking the coercion signals tumors use, drugs like checkpoint inhibitors can re-awaken the immune system’s ability to recognize and destroy cancer cells.
Metabolic Rewiring in Cancer Cells
Cancer cells do not just grow differently from normal cells; they eat differently too. Most healthy cells generate energy efficiently by burning glucose with oxygen in their mitochondria. Cancer cells shift toward a less efficient process: they consume far more glucose than normal cells and convert much of it to lactate, even when oxygen is plentiful. This behavior, known as the Warburg effect, was first observed nearly a century ago and remains one of the hallmarks of malignant metabolism.20PubMed Central. The Warburg Effect: How Does it Benefit Cancer Cells?
Why would cancer cells choose a less energy-efficient path? The current understanding is that the Warburg effect is not actually about energy at all. Rapid glucose breakdown generates a surplus of chemical building blocks that cancer cells can funnel into making new DNA, proteins, and membranes for daughter cells. It also produces metabolic byproducts that acidify the local environment, which can hinder immune cells and promote invasion. This metabolic reprogramming is so consistent across cancer types that it forms the basis of PET scanning, where a radioactive glucose tracer highlights tumors precisely because they absorb so much more glucose than surrounding normal tissue.
Staging, Grading, and Why They Matter
Once a neoplasm is identified as malignant, clinicians need a standardized way to describe how far it has progressed and how abnormal the cells look. Staging describes how far the cancer has spread. The internationally used TNM system evaluates three things: the size and extent of the primary tumor (T), whether cancer has reached nearby lymph nodes (N), and whether there are distant metastases (M). Each component is scored, and the combination determines an overall stage, usually from I (localized, early) through IV (widely spread).21PubMed Central. Tumor Staging and Grading: A Primer
Grading, by contrast, describes how abnormal the cells look under a microscope. Low-grade tumors have cells that still resemble their tissue of origin and tend to grow more slowly. High-grade tumors have cells that look highly disorganized and typically behave more aggressively. Both staging and grading feed into treatment decisions: a small, low-grade tumor might require only surgery, while a high-stage, high-grade cancer might need chemotherapy, radiation, and targeted therapies in combination.
About 8% of cancer patients also develop paraneoplastic syndromes, clinical symptoms caused not by the tumor pressing on structures or spreading to new sites, but by hormones, cytokines, or immune reactions triggered by the tumor itself. These syndromes can produce neurological symptoms, blood clotting problems, skin changes, or hormone imbalances that sometimes appear before the cancer itself is diagnosed.22Radiographics. Paraneoplastic Syndromes from Head to Toe: Pathophysiology, Imaging Features, and Workup
Inherited Versus Acquired Mutations
Most cancers are driven primarily by mutations that accumulate during a person’s lifetime, so-called somatic mutations. But some people are born with inherited variants in cancer-related genes that give them a head start down the path toward malignancy. Families carrying mutations in BRCA1 or BRCA2, for instance, face substantially elevated risks of breast and ovarian cancer. Lynch syndrome, caused by inherited defects in DNA mismatch repair genes, raises the risk of colorectal, endometrial, and several other cancers.
Research on the relationship between inherited genetic burden and acquired mutations has found a striking pattern. People who develop cancer at a younger age tend to carry a larger number of inherited variants affecting cancer-related genes, while those who develop cancer later in life accumulate more somatic mutations. The correlation between inherited variant burden and age at diagnosis was strong, and the average number of somatic mutations rose steadily in older age groups. There was also a strong negative relationship between the two: the more inherited variants a patient carried, the fewer somatic mutations their tumor needed to become malignant.23Nature Communications. Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden In practical terms, this means that people with heavy inherited genetic risk can develop cancer with fewer “bad luck” mutations along the way, which helps explain why hereditary cancer syndromes often strike decades earlier than their sporadic counterparts.
Peto’s Paradox and Cancer Across Species
If cancer is fundamentally a numbers game, with more cell divisions creating more opportunities for dangerous mutations, you would expect large, long-lived animals to have far more cancer than small, short-lived ones. A whale has thousands of times more cells than a mouse and lives decades longer. By simple math, whales should be riddled with tumors. They are not. This observation, known as Peto’s paradox, has puzzled biologists for decades.
Large-bodied species appear to have evolved more potent cancer-suppression mechanisms. Animals with a thousand times more cells than humans do not show increased cancer rates, implying their cells suppress malignancy far more effectively than ours do.24PubMed Central. Peto’s Paradox: evolution’s prescription for cancer prevention Elephants, for example, carry extra copies of the tumor-suppressor gene TP53. Naked mole-rats have unusual tissue structures that physically resist tumor growth. Bowhead whales, which can live over two hundred years, appear to have enhanced DNA-repair pathways. Studying how these species solve the cancer problem is an active area of comparative oncology research, with the hope that understanding their natural defenses could eventually point toward new prevention or treatment strategies in humans.